Investigation of Maternal and Fetal Exposure to an IgG2 Monoclonal Antibody Following Biweekly Intravaginal Administration to Cynomolgus Monkeys Throughout Pregnancy

  • Publication Date :
  • Publication Type : Journal Article
  • Author(s) : Moffat GJ, Davies R, Kwon G, Retter MW, Chellman GJ, Kanapuram S, Moore M, Loomis M, Wang W, Pyrah IT
  • Journal Name : Reproductive Toxicology

Reproductive Toxicology. 2014;48:132-137

Abstract: To assess the potential for male-mediated drug transfer to their female partner and/or developing conceptus, vaginal uptake of a monoclonal antibody(mAb) biotherapeutic was assessed in cynomolgus monkeys. A human IgG2 mAb (IgG2X; bound human and cynomolgus monkey neonatal Fc-receptor, FcRn, with similar high affinity) was administered intravaginally (IvG; 100mg/dose) to 5 pregnant cynomolgus monkeys biweekly from gestation day (gd) 21 to gd133. In all maternal samples collected before gd119, IgG2X plasma concentrations were below the limit of quantification (BLQ; <25ng/mL). After dosing on gd119 and 133, maternal IgG2X plasma concentrations remained BLQ in 3/5 monkeys and were very low in 2/5 (up to 116ng/mL; ∼0.01% of the IvG dose). IgG2X was BLQ in all fetal plasma samples. These data indicate that male-mediated mAb drug transfer via seminal fluid does not present a health risk to the female partner and is not bioavailable to the developing conceptus.

To download an open-access PDF copy, click here.

Contact Us

Health and Environmental Sciences Institute (HESI)
Phone: +1-202-659-8404
Fax: +1-202-659-3859

740 15th Street NW, Suite 600
Washington, DC 20005

Stay Informed

Sign up for our monthly e-newsletter.